Science News
Discover the news and inspiring materials from the world of biotechnology.
Monoclonal antibody targeting CD3 receptor preserves insulin secretion in early type 1 diabetes
Teplizumab, an anti-CD3 monoclonal antibody, was found to preserve the function of pancreatic β cells in newly diagnosed type 1 diabetes mellitus. Earlier, the drug has received FDA approval in the prevention of type 1 diabetes in high-risk individuals.
Learn more
EMA and FDA investigating cancer signal for CAR-T therapies
EMA and FDA have started a safety review of CAR-T therapies following the notification of 23 cases of T-cell malignancies. The investigation involves all registered CAR-T products, which are used for treating relapsed and treatment-resistant hematologic malignancies.
Learn more
Antisense therapy fails to delay the progression of Huntignton’s disease
A trial of investigational antisense therapy for Huntington’s disease, tominersen, has been halted early for lack of efficacy and possibly harm with more frequent dosing. However, the quest for effective therapy of Huntington’s disease is still ongoing and the developer of tominersen decided to continue research, this time enrolling younger patients with early disease.
Learn moreBispecific antibodies: success story continues
A great number of clinical studies confirmed high efficacy and safety of bispecific antibodies in the treatment of various cancers. Breaking results from another three, evaluating amivantamab, blinatumomab and tarlatamab, continue their success story.
Learn more
Moderna succeeds in the pivotal trial of RSV vaccine
An mRNA-based vaccine against respiratory syncytial virus (RSV) succeeded in a Phase III trial conducted in elderly subjects. Vaccine efficacy was 83.7% against RSV-related lower respiratory tract disease with at least two symptoms. It is hoped that the use of RSV vaccines along with influenza and COVID-19 immunization campaigns will further mitigate the morbidity and mortality of elderly people during the winter seasons.
Learn more
A new affordable HPV vaccine will help fight cervical cancer
Novel HPV vaccine manufactured by Serum Institute of India (Cervavac®) elicits comparable immune responses and is as safe as the original HPV vaccine. Availability of a cheaper version of HPV vaccine can foster the global efforts to reduce the incidence of cervical cancer.
Learn more
Researchers infect human volunteers with Zika virus in a quest for effective vaccine
Zika virus infection in pregnancy has been associated with microcephaly in newborns. In a pioneering experiment, female volunteers were challenged with live Zika virus and monitored for viral shedding, symptoms and immune responses. Researchers hope that human challenge experiments will speed up the development of novel vaccines and antiviral medications.
Learn more
The power of antibody-drug conjugates revealed in recent cancer trials
A new treatment combination containing antibody-drug conjugate called enfortumab vedotin, doubled the survival of patients with metastatic bladder cancer compared with the standard chemotherapy.
Learn more